<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12581566</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>10</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0169-5002</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>39</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Lung cancer (Amsterdam, Netherlands)</Title>
                <ISOAbbreviation>Lung Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>145-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We measured and compared the levels of plasma monocyte-derived microparticles (MDMP) and platelet activation markers [plasma platelet-derived microparticles (PDMP), CD62P binding to platelets; plt-CD62P, CD63 binding to platelets; plt-CD63], to develop a better understanding of their potential contribution to vascular complications of lung cancer. The concentrations of MDMP and PDMP in lung cancer patients were significantly higher (P &lt; 0.01) than those in normal subjects. Levels of plt-CD62P and plt-CD63 were significantly higher (P &lt; 0.001 for each) in lung cancer patients than in controls. Levels of sE-selectin were also higher in lung cancer patients than in control subjects. MDMP correlated positively with plt-CD62P, plt-CD63, and PDMP with its relation to PDMP being particularly significant. The number of MDMPs and PDMPs are patients who are non-small cell lung cancer were significantly higher than that in small cell lung cancer patients. In addition, levels of sE-selectin were higher in non-small cell lung cancer than in small cell lung cancer patients. These findings suggest that elevated MDMPs may be a sign of vascular complication in lung cancer patients, particularly those who suffer from non-small cell lung cancer.</AbstractText>
                <CopyrightInformation>Copyright 2002 Elsevier Science Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kanazawa</LastName>
                    <ForeName>Shigenori</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>The First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8507, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>Shosaku</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuwana</LastName>
                    <ForeName>Midori</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muramatsu</LastName>
                    <ForeName>Mikiko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Kazuyuki</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukuhara</LastName>
                    <ForeName>Shirou</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Lung Cancer</MedlineTA>
            <NlmUniqueID>8800805</NlmUniqueID>
            <ISSNLinking>0169-5002</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Annexin A5</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>E-Selectin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tumor Markers, Biological</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Annexin A5</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Platelets</DescriptorName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">E-Selectin</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">blood</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Monocytes</DescriptorName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Peripheral Vascular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Platelet Activation</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName>
                <QualifierName MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12581566</ArticleId>
            <ArticleId IdType="pii">S0169500202004415</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
